Meta-analysis · people

Retatrutide: top odds of 15% or more weight loss across 19 trials

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

In this pooled look at 19 trials, retatrutide led on reaching large weight loss but came with the highest side-effect risk of the drugs compared.

Kind
Meta-analysis
Studied in
People
Number studied
29506
Published
2025
Journal
Obesity (Silver Spring)

What they tested

The team set out to compare how well, and how safely, GLP-1 drugs, dual agonists and retatrutide help adults with overweight or obesity lose weight.

How the study was done

A systematic review and Bayesian network meta-analysis, a method that pools and ranks results from many trials, of 19 randomized controlled trials in 29,506 adults with a BMI of 25 kg/m2 or more. It compared liraglutide, semaglutide, survodutide, tirzepatide, retatrutide and placebo on outcomes measured at 36 weeks or later.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Retatrutide and the dual agonists each reached an average weight change of -11.0 kg, ahead of the GLP-1 drugs at -9.0 kg. For reaching 15% or more weight loss, retatrutide had an odds ratio (a measure of how much more likely an outcome is) of 54.6, followed by dual agonists at 16.4 and GLP-1 drugs at 9.0. Retatrutide also carried the highest risk of side effects. Having type 2 diabetes cut weight loss by 4.338 kg with GLP-1 drugs and by 5.016 kg with dual agonists, while groups with more women or a higher BMI did better.

What it doesn’t show

This study pooled 19 earlier trials rather than running a new one, and it grouped GLP-1 drugs and dual agonists into classes. It covers only adults with a BMI of 25 kg/m2 or more, with outcomes at 36 weeks or later.

The paper

Sinha and Ghosal Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity (Silver Spring). 2025.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo